Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Core EPS: $2.46 in Q3 2026, up 9.3% from a year earlier. That is the highest of the 11 quarters on record here.
Latest, Q3 2026
2.46
Period ended Sep 30, 2026
Change on a year earlier
+9.3%
2.25 in Q3 2025
History
11 quarters
Since Q1 2024
Sources
7
Documents cited below
Where the Q3 2026 figure comes from
“|| Core basic earnings per share (USD) | 2.46 | 2.25 | 9 | 8 | 6.85 | 6.94 | -1 | -3”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core EPS (USD/share) ($) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 2.46 | +9.3% | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | 2.41 | -0.4% | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2026 | Mar 31, 2026 | 1.99 | -12.7% | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2025 | Dec 31, 2025 | 2.03 | +2.5% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2025 | Sep 30, 2025 | 2.25 | +9.2% | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2025 | Jun 30, 2025 | 2.42 | +22.8% | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2025 | Mar 31, 2025 | 2.28 | +26.7% | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2024 | Dec 31, 2024 | 1.98 | – | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2024 | Sep 30, 2024 | 2.06 | – | Novartis Form 6-K (0001114448-25-000003) ↗ |
| Q2 2024 | Jun 30, 2024 | 1.97 | – | Novartis Form 6-K (0001370368-25-000012) ↗ |
| Q1 2024 | Mar 31, 2024 | 1.80 | – | Novartis Form 6-K (0001370368-25-000010) ↗ |
Breakdown
What makes up core EPS
Cite this data
StockData. (2026). Novartis Core EPS ($), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/core-eps-basic
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.